Alexis Tabah1, Jan De Waele2, Jeffrey Lipman3, Jean Ralph Zahar4, Menino Osbert Cotta5, Greg Barton6, Jean-Francois Timsit7, Jason A Roberts5. 1. Intensive Care Unit, The Royal Brisbane and Women's Hospital, Brisbane, Australia Burns, Trauma, and Critical Care Research Centre, The University of Queensland, Brisbane, Australia alextabah@gmail.com. 2. Department of Critical Care Medicine, Ghent University Hospital, Ghent, Belgium. 3. Intensive Care Unit, The Royal Brisbane and Women's Hospital, Brisbane, Australia Burns, Trauma, and Critical Care Research Centre, The University of Queensland, Brisbane, Australia Faculty of Health, Queensland University of Technology, Brisbane, Australia. 4. Unité de Prévention et de Lutte contre les Infections Nosocomiales, CHU Angers - Université D'Angers, Angers, France. 5. Intensive Care Unit, The Royal Brisbane and Women's Hospital, Brisbane, Australia Burns, Trauma, and Critical Care Research Centre, The University of Queensland, Brisbane, Australia. 6. Pharmacy Department, St Helens and Knowsley Teaching Hospitals NHS Trust, Liverpool, UK School of Pharmacy & Biomolecular Sciences, Liverpool John Moores University, Liverpool, UK. 7. APHP - Hopital Bichat - Reanimation Medicale et des maladies infectieuses, F-75018 Paris, France UMR 1137 - IAME Team 5 - DeSCID: Decision SCiences in Infectious Diseases, control and care; Inserm/Univ Paris Diderot, Sorbonne Paris Cité, F-75018 Paris, France.
Abstract
OBJECTIVES: There is little evidence and few guidelines to inform the most appropriate dosing and monitoring for antimicrobials in the ICU. We aimed to survey current practices around the world. METHODS: An online structured questionnaire was developed and sent by e-mail to obtain information on local antimicrobial prescribing practices for glycopeptides, piperacillin/tazobactam, carbapenems, aminoglycosides and colistin. RESULTS: A total of 402 professionals from 328 hospitals in 53 countries responded, of whom 78% were specialists in intensive care medicine (41% intensive care, 30% anaesthesiology, 14% internal medicine) and 12% were pharmacists. Vancomycin was used as a continuous infusion in 31% of units at a median (IQR) daily dose of 25 (25-30) mg/kg. Piperacillin/tazobactam was used as an extended infusion by 22% and as a continuous infusion by 7%. An extended infusion of carbapenem (meropenem or imipenem) was used by 27% and a continuous infusion by 5%. Colistin was used at a daily dose of 7.5 (3.9-9) million IU (MIU)/day, predominantly as a short infusion. The most commonly used aminoglycosides were gentamicin (55%) followed by amikacin (40%), with administration as a single daily dose reported in 94% of the cases. Gentamicin was used at a daily dose of 5 (5-6) mg/day and amikacin at a daily dose of 15 (15-20) mg/day. Therapeutic drug monitoring of vancomycin, piperacillin/tazobactam and meropenem was used by 74%, 1% and 2% of the respondents, respectively. Peak aminoglycoside concentrations were sampled daily by 28% and trough concentrations in all patients by 61% of the respondents. CONCLUSIONS: We found wide variability in reported practices for antibiotic dosing and monitoring. Research is required to develop evidence-based guidelines to standardize practices.
OBJECTIVES: There is little evidence and few guidelines to inform the most appropriate dosing and monitoring for antimicrobials in the ICU. We aimed to survey current practices around the world. METHODS: An online structured questionnaire was developed and sent by e-mail to obtain information on local antimicrobial prescribing practices for glycopeptides, piperacillin/tazobactam, carbapenems, aminoglycosides and colistin. RESULTS: A total of 402 professionals from 328 hospitals in 53 countries responded, of whom 78% were specialists in intensive care medicine (41% intensive care, 30% anaesthesiology, 14% internal medicine) and 12% were pharmacists. Vancomycin was used as a continuous infusion in 31% of units at a median (IQR) daily dose of 25 (25-30) mg/kg. Piperacillin/tazobactam was used as an extended infusion by 22% and as a continuous infusion by 7%. An extended infusion of carbapenem (meropenem or imipenem) was used by 27% and a continuous infusion by 5%. Colistin was used at a daily dose of 7.5 (3.9-9) million IU (MIU)/day, predominantly as a short infusion. The most commonly used aminoglycosides were gentamicin (55%) followed by amikacin (40%), with administration as a single daily dose reported in 94% of the cases. Gentamicin was used at a daily dose of 5 (5-6) mg/day and amikacin at a daily dose of 15 (15-20) mg/day. Therapeutic drug monitoring of vancomycin, piperacillin/tazobactam and meropenem was used by 74%, 1% and 2% of the respondents, respectively. Peak aminoglycoside concentrations were sampled daily by 28% and trough concentrations in all patients by 61% of the respondents. CONCLUSIONS: We found wide variability in reported practices for antibiotic dosing and monitoring. Research is required to develop evidence-based guidelines to standardize practices.
Authors: Sofie Dhaese; Aaron Heffernan; David Liu; Mohd Hafiz Abdul-Aziz; Veronique Stove; Vincent H Tam; Jeffrey Lipman; Jason A Roberts; Jan J De Waele Journal: Clin Pharmacokinet Date: 2020-10 Impact factor: 6.447
Authors: Phillip J Bergen; Jürgen B Bulitta; Carl M J Kirkpatrick; Kate E Rogers; Megan J McGregor; Steven C Wallis; David L Paterson; Roger L Nation; Jeffrey Lipman; Jason A Roberts; Cornelia B Landersdorfer Journal: Antimicrob Agents Chemother Date: 2017-04-24 Impact factor: 5.191
Authors: Cornelia B Landersdorfer; Vanessa E Rees; Rajbharan Yadav; Kate E Rogers; Tae Hwan Kim; Phillip J Bergen; Soon-Ee Cheah; John D Boyce; Anton Y Peleg; Antonio Oliver; Beom Soo Shin; Roger L Nation; Jürgen B Bulitta Journal: Antimicrob Agents Chemother Date: 2018-03-27 Impact factor: 5.191
Authors: Rajbharan Yadav; Phillip J Bergen; Kate E Rogers; Carl M J Kirkpatrick; Steven C Wallis; Yuling Huang; Jürgen B Bulitta; David L Paterson; Jeffrey Lipman; Roger L Nation; Jason A Roberts; Cornelia B Landersdorfer Journal: Antimicrob Agents Chemother Date: 2019-12-20 Impact factor: 5.191
Authors: Rajbharan Yadav; Kate E Rogers; Phillip J Bergen; Jürgen B Bulitta; Carl M J Kirkpatrick; Steven C Wallis; David L Paterson; Roger L Nation; Jeffrey Lipman; Jason A Roberts; Cornelia B Landersdorfer Journal: Antimicrob Agents Chemother Date: 2018-04-26 Impact factor: 5.191
Authors: Jan J De Waele; Murat Akova; Massimo Antonelli; Rafael Canton; Jean Carlet; Daniel De Backer; George Dimopoulos; José Garnacho-Montero; Jozef Kesecioglu; Jeffrey Lipman; Mervyn Mer; José-Artur Paiva; Mario Poljak; Jason A Roberts; Jesus Rodriguez Bano; Jean-François Timsit; Jean-Ralph Zahar; Matteo Bassetti Journal: Intensive Care Med Date: 2017-12-29 Impact factor: 17.440
Authors: Rachel D Savage; Robert A Fowler; Asgar H Rishu; Sean M Bagshaw; Deborah Cook; Peter Dodek; Richard Hall; Anand Kumar; François Lamontagne; François Lauzier; John Marshall; Claudio M Martin; Lauralyn McIntyre; John Muscedere; Steven Reynolds; Henry T Stelfox; Nick Daneman Journal: CMAJ Open Date: 2016-10-13
Authors: H Woksepp; A Hällgren; S Borgström; F Kullberg; A Wimmerstedt; A Oscarsson; P Nordlund; M-L Lindholm; J Bonnedahl; L Brudin; B Carlsson; T Schön Journal: Eur J Clin Microbiol Infect Dis Date: 2016-11-04 Impact factor: 3.267
Authors: Stijn Jonckheere; Nikolaas De Neve; Jan Verbeke; Koen De Decker; Inger Brandt; An Boel; Jan Van Bocxlaer; Michel M R F Struys; Pieter J Colin Journal: Antimicrob Agents Chemother Date: 2019-12-20 Impact factor: 5.191